Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Dr. Adil Ali
Lexicon Pharmaceuticals, Inc.'s obesity drug, LX9851, is the subject of an exclusive license agreement with Novo Nordisk worth up to $1bn.
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
London · 15–19 November 2026
Explore Onyx’s independent guide to the events and make the most of your week in London.
